Ascentage Pharma Group International - Unsponsored ADR AAPG
14.86
(0.37)
(2.43%)
as of 25 Sep
- Market cap
- $1.4B
- P/E
- —
Follow AAPG
A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.
| Jun '26 | Dec '25 | Jun '25 | |
|---|---|---|---|
Net Income |
(230.90) | (230.90) | (182.51) |
Operating Cash Flow |
(317.58) | (331.83) | — |
Capital expenditures |
(11.29) | (15.89) | — |
Other investing activities |
(56.84) | (186.80) | — |
Investing cash flow |
(73.54) | (207.65) | — |
Repayment/Issuance of Debt (Net) |
2.25 | (13.60) | — |
Other financial activities |
(27.95) | (35.41) | — |
Financing cash flow |
471.83 | 511.71 | — |
Exchange Rate Adjustment |
(14.33) | (2.91) | — |
Change in Cash |
66.38 | (30.68) | — |
Beginning Cash |
589.00 | 597.93 | — |
Ending Cash |
655.38 | 567.25 | — |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 |
Investments Change (Net) |
(5.41) | (4.97) | — |
Issuance/Purchase of Shares |
473.51 | 538.53 | — |
In millions of $ except per-share values · columns are period end dates